PTS202 (para-toluenesulfonamide)

PTS202 is a small molecule therapeutic candidate developed by Gongwin Biopharm Holdings for the treatment of head and neck cancer. It is a formulation of para-toluenesulfonamide (PTS) designed for administration via direct intratumoral injection. The drug operates through a chemical ablation mechanism, where the high concentration of the compound induces rapid dehydration and necrosis of tumor cells upon contact. This localized approach is intended to debulk tumors and alleviate obstructive symptoms in patients with advanced or recurrent head and neck cancers, particularly when surgical resection is not feasible. PTS202 is part of Gongwin's broader PTS platform, which utilizes the same active ingredient for various oncology indications, including lung and liver cancers.

Other names

4-toluenesulfonamidep-toluenesulfonamide甲苯磺醯胺